Search hospitals

>

Alabama

>

Birmingham

University of Alabama at Birmingham Cancer Center

Claim this profile

Birmingham, Alabama 35233

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Brain Tumor

Conducts research for Ovarian Cancer

663 reported clinical trials

37 medical researchers

Photo of University of Alabama at Birmingham Cancer Center in BirminghamPhoto of University of Alabama at Birmingham Cancer Center in Birmingham

Summary

University of Alabama at Birmingham Cancer Center is a medical facility located in Birmingham, Alabama. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Brain Tumor, Ovarian Cancer and other specialties. University of Alabama at Birmingham Cancer Center is involved with conducting 663 clinical trials across 592 conditions. There are 37 research doctors associated with this hospital, such as Victor T. Lin, Rebecca C. Arend, Amitkumar Mehta, MD, and Pankit Vachhani.

Area of expertise

1

Cancer

Global Leader

University of Alabama at Birmingham Cancer Center has run 116 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative
2

Breast Cancer

Global Leader

University of Alabama at Birmingham Cancer Center has run 63 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
HER2 positive

Top PIs

Clinical Trials running at University of Alabama at Birmingham Cancer Center

Cancer

Ovarian Cancer

Bladder Cancer

Lung Cancer

Skin Cancer

Esophageal cancer

Kidney Cancer

Bladder Carcinoma

Cervical Cancer

Breast Cancer

Image of trial facility.

Cooling/Compression Therapy

for Chemotherapy-Induced Peripheral Neuropathy

This trial tests three methods to prevent nerve damage in patients receiving taxane chemotherapy. The methods involve using special wraps that either cool the limbs, apply steady pressure, or apply gentle pressure that comes and goes. These approaches aim to protect nerves from the harmful effects of chemotherapy drugs. Cooling the limbs has been well-tolerated and is a reasonable option to prevent nerve damage in patients receiving taxane-based treatments.

Recruiting

2 awards

Phase 3

Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Recruiting

2 awards

Phase 3

13 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Alabama at Birmingham Cancer Center?

Where is University of Alabama at Birmingham Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Alabama at Birmingham Cancer Center accept?

What awards or recognition has University of Alabama at Birmingham Cancer Center received?